AstraZeneca said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

So, how does metabolic bariatric surgery help those with genetic obesity? Hormonal Regulation: Certain bariatric procedures, ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

Research on fruit flies reveals how gut hormones influence insulin release and aging, with potential implications for diabetes, obesity, and healthy aging in humans. Gut hormone NPF in flies ...

On the other hand, semaglutide’s close competitor tirzepatide—a drug by US pharma firm Eli Lilly and Company which is ...

Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...

Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...

Obesity in an ageing population 'is biggest issue for the ... a new class of drug which mimics the action of GLP-1 - a naturally occurring gut hormone which is released after eating. Their effect is ...

The key to the new combination is a second gut hormone, amylin, that’s targeted by cagrilintide ... it will give the Danish ...